Refractory Thyroid Cancer: A Paradigm Shift in Treatment Is Not Far Off
Author:
Affiliation:
1. Memorial Sloan-Kettering Cancer Center, New York, NY
Publisher
American Society of Clinical Oncology (ASCO)
Subject
Cancer Research,Oncology
Link
http://ascopubs.org/doi/pdfdirect/10.1200/JCO.2008.17.3682
Reference37 articles.
1. Axitinib Is an Active Treatment for All Histologic Subtypes of Advanced Thyroid Cancer: Results From a Phase II Study
2. Phase II Trial of Sorafenib in Advanced Thyroid Cancer
3. Management Guidelines for Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Taskforce
4. Long-term survival rates of cancer patients achieved by the end of the 20th century: a period analysis
5. Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer
Cited by 52 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. The effects of Aurora Kinase inhibition on thyroid cancer growth and sensitivity to MAPK-directed therapies;Cancer Biology & Therapy;2024-03-23
2. Using 18F-FDG-PET/CT Metrics to Predict Survival in Ra-Dio-Iodine Refractory Thyroid Cancers;Diagnostics;2022-09-30
3. The role of ATP-binding cassette transporter genes in the metastatic process of epithelial thyroid carcinoma with aggressive behavior;Unraveling the Complexities of Metastasis;2022
4. Inhibition of BRAF and ERK1/2 has synergistic effects on thyroid cancer growth in vitro and in vivo;Molecular Carcinogenesis;2021-02-17
5. Therapeutic targets of cancer drugs: Modulation by melatonin;Life Sciences;2021-02
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3